AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...

AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

Investing.com - JPMorgan has reiterated its Overweight rating and $200.00 price target on AbbVie (NYSE: ABBV), currently valued at $337 billion, ahead of the company’s second-quarter earnings ...

AbbVie (ABBV) closed at $182.31 in the latest trading session, marking a -2.4% move from the prior day.

The expectation is for Q2 earnings to increase by +5% from the same period last year on +4% higher revenues. This will be a material deceleration from the growth trend of recent quarters and will ...

In other recent news, AbbVie has announced an exclusive licensing agreement with IGI Therapeutics for ISB 2001, a trispecific antibody targeting multiple myeloma.

Making Sense of Earnings Expectations for 2025 Q2 and Beyond The start of Q2 coincided with heightened tariff uncertainty following the punitive April 2 nd tariff announcements.

AbbVie is expected to post earnings of $3.24 per share for the current quarter, representing a year-over-year change of +22.3%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.